Canopy Growth (CGC) Q3 2026 earnings review
Domestic Turnaround, International Drag
Canopy Growth delivered a mixed Q3. While total revenue was flat at $75M, the composition of that revenue shifted positively. The core Canadian business is accelerating, with Adult-Use up 8% and Medical up 15%. However, this was offset by a sharp 31% YoY drop in International Cannabis and a 9% contraction in Storz & Bickel. Cost discipline is the real story here: SG&A cuts drove Adjusted EBITDA loss down to just $3M (vs $3.5M YoY). While the 'going concern' risk has faded due to massive equity issuance, the company remains unprofitable with a timeline to positive EBITDA pushed to FY2027.
🐂 Bull Case
After years of declines, the domestic engine is firing. Canadian Medical grew 15% YoY and Adult-Use grew 8% YoY, driven by product innovation (Claybourne pre-rolls, new vapes) and better retailer engagement. This proves the core brand equity survives.
Strict cost controls have reduced the Adjusted EBITDA loss to near breakeven (-$3M). Free cash outflow improved to $19M. With $371M in cash on hand (largely from dilution), the immediate liquidity crisis is off the table.
🐻 Bear Case
International markets—supposedly the high-margin growth engine—reversed sharply, falling 31% YoY. Management cites supply chain tooling, but a drop of this magnitude raises questions about demand durability in Europe.
Consolidated gross margin fell 300bps YoY to 29%. Mix shift hurt: high-margin International sales fell, and Storz & Bickel margins contracted due to tariffs and lower operating leverage.
⚖️ Verdict: ⚪
Neutral. The stabilization in Canada is a significant achievement, but the International collapse and margin compression prevent a higher grade. The balance sheet is safe only because of massive dilution. Execution risk remains high for the FY27 profitability target.
Key Themes
Canadian Medical Strength
Accelerating. Canadian Medical revenue grew 15% YoY to $23M. This segment is sticky, high-margin, and less competitive than the rec market. Growth was driven by an increase in insured patients and larger basket sizes, validating the strategy to focus on this moat.
Storz & Bickel Saturation?
Decelerating. Despite a seasonal Q3 bounce (+45% sequentially), S&B revenue fell 9% YoY to $23M. Gross margins in this segment also compressed from 40% to 37% due to US tariffs. This 'jewel in the crown' asset is showing signs of growth fatigue and macro sensitivity.
Dilution Funded Survival
While cash increased to $371M (from $113M at FY start), it wasn't from operations. Financing activities generated $285M YTD, primarily from share/warrant issuance. The 'going concern' removal was purchased with shareholder equity, not earned through operations.
Innovation Rescuing Adult-Use
Accelerating. Canadian Adult-Use revenue grew 8% YoY to $23M. This reverses a long trend of declines. Drivers are specific: Claybourne infused pre-rolls and new All-In-One vapes. The company is finally successfully commercializing NPD (New Product Development) rather than just losing share.
International Volatility
Reversing. International revenue fell 31% YoY to $6.2M. While management notes a 22% sequential improvement due to resolved supply bottlenecks in Europe, the YoY hole is deep. This segment was pitched as the high-growth future; currently, it is a drag.
Cost Structure Rightsizing
Stable. SG&A expenses excluding one-offs decreased 12% YoY. The company has captured $29M in annualized savings since March 2025. This discipline is the primary reason EBITDA losses are narrowing despite flat top-line revenue.
Other KPIs
Improved 17% from -$3.5M in 25Q3. The company is flirting with breakeven but can't quite cross the line due to gross margin compression offsetting SG&A cuts.
Deteriorating. Down from 32% a year ago. Cannabis margins fell to 25% (from 28%) due to lower International mix. S&B margins fell to 37% (from 40%) due to tariffs. This structural decline is alarming during a revenue recovery.
Improving. Outflow narrowed from $28M in the prior year. However, the company is still burning cash operationally, necessitating the recent equity raises.
Guidance
Management reaffirmed the goal to achieve positive Adjusted EBITDA during fiscal 2027. This implies FY2026 will finish in the red. This is a delay from previous 'near-term' optimism seen in early FY26 calls.
Accelerating. Management cited sequential improvement (+22% QoQ) and supply chain fixes as a basis for continued recovery in Europe.
Key Questions
International Margin Integrity
International revenue fell 31% YoY, hurting consolidated margins. As you ramp supply back up, will margins return to the 40%+ range seen in prior years, or has the pricing environment in Germany/Poland permanently shifted?
Storz & Bickel Growth Floor
S&B is down 9% YoY despite a new product launch (VEAZY). Is the premium vaporizer market saturated, and how much of the margin compression (40% -> 37%) is structural tariffs vs temporary volume deleverage?
Cash Burn vs Dilution
You raised substantial cash via equity to fix the balance sheet. With FCF still negative (-$19M), do you have sufficient liquidity to reach the FY27 profitability target without further diluting shareholders?